Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Print: 2151-8017
ISSN Online: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014008152
pages 255-273

Venoms Can Be a Boon for Cancer Patients

Sudhir Kumar
IGNOU-I2IT Centre of Excellence for Advanced Education and Research, Pune, Maharashtra, India
Puja Sarkar
IGNOU-I2IT Centre of Excellence for Advanced Education and Research, Pune, Maharashtra, India
Ruchi Jain
Organic Chemistry Division, CSIR National Chemical Laboratory, Pune, Maharashtra, India

ABSTRACT

Cancer is one of the leading causes of death worldwide. Remarkable progress has recently been made toward understanding the proposed hallmarks of cancer development and treatment. Treatment modalities comprise radiation therapy, surgery, chemotherapy, immunotherapy, and hormonal therapy. The use of chemotherapeutics currently remains the predominant option for cancer therapy. One of the major problems with successful cancer therapy using chemotherapeutics is that patients often do not respond or eventually develop resistance after initial treatment. This issue has led to the increased use of anticancer drugs developed from natural resources. The biodiversity of venoms and toxins make them a unique source from which new therapeutics may be developed. Some molecules of venom are under clinical trials and may be utilized in anticancer drug development in the near future. This review discusses the anticancer potential of different venoms, surveys the pharmacology of venom peptides, and assesses their therapeutic prospects.


Articles with similar content:

Role of Block Copolymer Nanoconstructs in Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 2
H. G. Agrawal, K. K. Upadhyay, C. Schatz, Sebastian Lecommandoux, J. F. Le Meins, Ambikanandan Misra, C. Upadhyay
From Targets to Targeted Therapies in Hepatocellular Carcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Melchiorre Cervello, Antonella Cusimano, Maria Rita Emma, Antonina Azzolina, Giuseppa Augello, James A. McCubrey, Daniele Balasus
Current Perspectives in Immunotherapy for Liver Cancer
Critical Reviews™ in Oncogenesis, Vol.25, 2020, issue 1
Bassam Ghabach, Kalyani Narra, Riyaz Basha, Christoffer Briggs Lambring
Solid Lipid Nanoparticles: Vital Characteristics and Prospective Applications in Cancer Treatment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 6
Lucia R. Tefas, Diana Tudor, Elena Diana Olteanu, Marcela Achim, Claudia Burz, Iuliana Nenu, Gabriela Adriana Filip, Ioana Baldea, Leontin F. Lazăr, Simona Clichici, Radu Iuga
Colorectal Cancer Management by Herbal Drug-Based Nanocarriers: An Overview
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.37, 2020, issue 1
Sujata P. Sawarkar, Krishna Baxi, Vritika Kulwal, Lokesh Kumar Bhatt